2020 US Drug Patent Litigation ResearchHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)2020 US Drug Patent Litigation ResearchGlobeNewswireJanuary 9, 2020ReblogShareTweetShareDublin, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The "Drug Patent Database Subscription: US Drug Patent Litigation" newsletter has been added to ResearchAndMarkets.com's offering. Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what's next. If you are expanding into new markets, looking inward for growth opportunities, or seeking to improve your current activities and need to find information quickly, this subscription can help.This subscription for the US Drug Patent Litigation portion of the database offers information on: US District Court Cases, Patent Infringement, Contract Disputes, Antitrust, etc. Patent Trial and Appeal Board, PTAB inter partes review, post-grant reviewThe subscription includes relevant context and ensures you have the information you need at your fingertips. This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches. The sophisticated algorithms are also tailored to help you extract valuable insights.With a single click, you can find answers to complex questions such as:Which drugs have no patents and no competitors?What are all the patents covering any given dosage form (e.g. injectables)?What is the earliest generic entry opportunity date for a drug with dozens of patents?The subscription focuses on delivering the greatest value and lowest cost by directing attention to high-impact problems, giving you the relevant information you need.Key Topics Covered:
US District Court Cases Patent Infringement, Contract Disputes, Antitrust, etc. Patent Trial and Appeal Board Some of the Companies Mentioned Include: 3M PharmaceuticalsAbbott LaboratoriesAbbVieAcorda TherapeuticsActavisAllerganAlmirallAmgenAnfatisAstellas PharmaAstraZenecaAvax TechnologiesBioconBiolexBionovoBiotecnolBoehringer-IngelheimBosnalijekBristol-Myers SquibbBTG plcCadila HealthcareCatalentThe Cathay Drug Co., Inc.CelgeneCephalonChugai Pharmaceutical Co.CinnaGenCiplaCoCo TherapeuticsConcordia HealthcareDaburDaiichi SankyoDiabetology LtdDr. Reddy's LaboratoriesEisaiElder PharmaceuticalsGalderma LaboratoriesGedeon Richter Ltd.Gilead SciencesGlatt groupGlaxoSmithKlineGPC BiotechHovioneInterphil LaboratoriesIonis PharmaceuticalsIpca LaboratoriesIpsenJanssen PharmaceuticaJenapharmJohnson & JohnsonJulpharJuno TherapeuticsKimia FarmaMcGuffMedinfarMelior DiscoveryMenariniMerck & Co.Mitsubishi PharmaNovartisNovo NordiskNoxxonOtsuka Pharmaceutical Co.Panacea BiotecPatheonPerrigoPfizerProcter & GamblePurdue PharmaRanbaxy LaboratoriesReckitt BenckiserRenovo PLCRepligenRubicon ResearchSalix PharmaceuticalsSanofiServier LaboratoriesShionogiShire plcSIGA TechnologiesSigma PharmaceuticalsSinopharm GroupSolvay GroupSun PharmaceuticalSunovionTakeda Pharmaceutical Co.TaslyTeva PharmaceuticalsUCBUnichem LaboratoriesUSV Private LimitedWockhardtYuhan CorporationFor more information about this newsletter visit https://www.researchandmarkets.com/r/uw28tmAbout ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceStock Market Live Updates: Stocks stretch to new records; United Steel plunges on layoffs, profit warningYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance VideoClimate change will reshape finance: BlackRock CEOYahoo Finance Video